Company Update: Allergan Inc (NYSE:AGN) – Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215

Amgen (AMGN) and Allergan plc. (NYSE:AGN) today announced a Phase 3 study of biosimilar candidate ABP 215 met its primary and secondary endpoints. The study evaluated the efficacy and safety of ABP 215 compared . . . → Read More: Company Update: Allergan Inc (NYSE:AGN) – Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215 Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215 Company Update: Allergan Inc (NYSE:AGN) – Allergan Successfully Completes Oculeve Acquisition Company Update (NYSE:AGN): Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA